The calcium sensitiser levosimendan, which is used as an inodilator to treat decompensated heart failure, may also exhibit anti-inflammatory properties. We examined whether treatment with levosimendan improves cardiopulmonary function and is substantially beneficial to the inflammatory response in acute respiratory response syndrome (ARDS). Levosimendan was administered intravenously in a new experimental porcine model of ARDS. For comparison, we used milrinone, another well-known inotropic agent. Our results demonstrated that levosimendan intravenously improved hemodynamics and lung function in a porcine ARDS model. Significant beneficial alterations in the inflammatory response and lung injury were not detected
Classic inotropic agents provide short-term haemodynamic improvement in patients with heart failure,...
Levosimendan is a new agent for the treatment of acute heart failure. Levosimendan acts via compleme...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...
Levosimendan is a calcium sensitizer and its inotropic effect is mainly attributed to the troponin C...
Heart failure is characterised by decreased cardiac output, which results in the development of both...
ABSTRACT Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium s...
Levosimendan is an inodilator that promotes cardiac contractility primarily through calcium sensitiz...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Background: Levosimendan has been proposed as an attractive alternative to adrenergic agents for the...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Objective: Acute respiratory distress syndrome (ARDS) is frequently associated with increased pulmon...
Levosimendan has a calcium-sensitizing effect in the myocardium and opens adenosine-triphosphate-sen...
Sepsis-related cardiovascular dysfunction associated with fluid-unresponsive tissue hypoperfusion mi...
KISA, Ucler/0000-0002-8131-6810; Yaman, Ferda/0000-0001-6847-1720WOS: 000416066800003PubMed: 2905282...
Classic inotropic agents provide short-term haemodynamic improvement in patients with heart failure,...
Levosimendan is a new agent for the treatment of acute heart failure. Levosimendan acts via compleme...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...
Levosimendan is a calcium sensitizer and its inotropic effect is mainly attributed to the troponin C...
Heart failure is characterised by decreased cardiac output, which results in the development of both...
ABSTRACT Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium s...
Levosimendan is an inodilator that promotes cardiac contractility primarily through calcium sensitiz...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Background: Levosimendan has been proposed as an attractive alternative to adrenergic agents for the...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Objective: Acute respiratory distress syndrome (ARDS) is frequently associated with increased pulmon...
Levosimendan has a calcium-sensitizing effect in the myocardium and opens adenosine-triphosphate-sen...
Sepsis-related cardiovascular dysfunction associated with fluid-unresponsive tissue hypoperfusion mi...
KISA, Ucler/0000-0002-8131-6810; Yaman, Ferda/0000-0001-6847-1720WOS: 000416066800003PubMed: 2905282...
Classic inotropic agents provide short-term haemodynamic improvement in patients with heart failure,...
Levosimendan is a new agent for the treatment of acute heart failure. Levosimendan acts via compleme...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...